In 2024, the Alzheimer’s Association (AA) workgroup, led by Clifford Jack, proposed revised criteria emphasizing the biological definition of AD, centered on the ATN model, which incorporates biomarkers for Aβ, tau, and neurodegeneration. Here, MAPT is linked to Alzheimer disease.